48.92
+2.73%
Close of 9 Nov 2026, in HKD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About WuXi Biologics (Cayman)
Its shares trade on HKEX under the ticker 2269.HK. It has been listed since 13 June 2017. In the fiscal year to 31 December 2025, it reported revenue of CN¥25.36bn and net income of CN¥5.71bn. At that date it held total assets of CN¥74.16bn and shareholders' equity of CN¥55.01bn.
Wuxi Biologics (Cayman), Inc. is an investment holding company, which engages in the discovery, development and manufacture of biologics services. The company is headquartered in Wuxi, Jiangsu. The company went IPO on 2017-06-13. The firm's technology platforms include WuXiBody TM bispecific antibody technology platform and antibody drug conjugates (ADC) technology platform. The company has brought in several new projects into its pipeline. The firm has a vaccine manufacturing facility and produces vaccines for customers to supply the global market. The firm conducts its businesses within the China market and to overseas markets, such as North America, Europe and other markets.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Life Sciences Tools & Services
- Listed since
- 13 Jun 2017
- Employees
- 5,694
- Website
- wuxibiologics.com ↗
Leadership
Pay as last reported
- Dr. Ge LiNon-Executive Chairman of the Board
- Dr. Zhisheng ChenChief Executive Officer, Executive Director, since 2014CN¥95.7m
- Mr. Ming TuChief Financial Officer
- Mr. Jian DongChief Executive Officer - WuXi Vaccines
- Dr. Sherry GuExecutive Vice President, Chief Technology Officer
- Dr. William AitchisonSenior Vice President and Head of US Operations Department
- Dr. Wei GuoSenior Vice President and Head of Global Manufacturing Department
- Dr. Juergen HindererSenior Vice President - Head of Global Engineering Department
- Mr. Hou Loh IngSenior Vice President, Head - Global Quality Department
- Mr. Angus TurnerSenior Vice President - Head of Global Business Development and Alliance Management
- Dr. Jijie GuPresident - Global Biologics Research, Chief Scientific Officer
- Dr. Xuejun GuExecutive Director, since 2025
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 95
- Environment
- 99
- Social
- 99
- Governance
- 86
- Direct emissions (scope 1)
- 38,346 t
- Energy emissions (scope 2)
- 160,308 t
- Value chain emissions (scope 3)
- 71,244 t
- Women in the workforce
- 54%
- Carbon reduction policy
- Yes
- Human rights policy
- Yes
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Strong brand reputation: WuXi Biologics (Cayman) Inc has established a strong reputation in the biologics industry, known for its high-quality services and expertise.
- Extensive capabilities: The company possesses state-of-the-art facilities, advanced technologies, and a broad range of capabilities in biologics development, manufacturing, and analytical testing.
- Strategic partnerships: WuXi Biologics has formed strategic partnerships with many leading pharmaceutical companies, enhancing its market position and facilitating business expansion.
- Global market presence: The company has a global footprint, allowing it to tap into diverse markets and reach a wide customer base.
Weaknesses
- Dependence on partners: WuXi Biologics relies heavily on partnerships for its business growth, which may expose it to risks associated with partner-related uncertainties or conflicts.
- Regulatory challenges: The biologics industry is subject to stringent regulatory frameworks, and any non-compliance or delays in obtaining necessary approvals could impact the company's operations.
- Limited diversification: The company's revenue is largely dependent on biologics development and manufacturing, making it vulnerable to fluctuations in the industry's demand or technological advancements.
Opportunities
- Growing demand for biologics: The increasing prevalence of complex diseases and the shift towards personalized medicine create ample opportunities for WuXi Biologics to cater to the rising demand for biologics development and manufacturing.
- Expansion into emerging markets: The company can explore entering and expanding operations in emerging markets, where the demand for biologics is on the rise and competition may be relatively lower.
- Technological advancements: Investing in research and development to leverage advancements in biotechnology can further enhance the company's capabilities and increase its competitive edge.
Threats
- Intense competition: The biologics industry is highly competitive, with numerous players offering similar services. WuXi Biologics must continuously innovate and differentiate itself to retain its market share.
- Intellectual property risks: The protection of intellectual property is crucial in the biologics sector. Unforeseen disputes or infringements on patents or proprietary technologies could negatively impact the company's business.
- Macroeconomic factors: Global economic fluctuations, changes in government policies, and currency exchange rate risks can affect the company's financial performance and operational stability.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.